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ABSTRACT The use of implantable ventricular assist devices for the treatment of advanced, decompensated
heart failure as a bridge to heart transplantation has experienced considerable evolution over the past
decade. Improvements in the management and prevention of serious adverse events, and introduction
of new continuous-flow rotary pumps that are smaller, more durable, and associated with fewer serious
adverse advents has expanded the use of this therapy to a larger population of patients for bridge to
transplant indication. doi: 10.1111/j.1540-8191.2010.00996.x (J Card Surg 2010;25:455-461)
BACKGROUND
Heart transplantation remains the most successful
treatment option for patients with advanced heart fail-
ure.1 As a consequence of limited donor availability,
mechanical circulatory support (MCS) in the form of
implantable ventricular assist device (VAD) therapy has
become an established treatment for patients with
advanced heart failure as a bridge to transplantation
(BTT).2–4 The successful clinical use of a ventricu-
lar assist device (VAD) as BTT therapy began in the
early 1980s.5 Donald Hill first reported the success-
ful utilization of the pneumatically actuated Pierce–
Donachy paracorporeal device as a BTT.5 In that same
year, Philip Oyer of Stanford University successfully
implanted the Novacor left ventricular assist device
(LVAD) as a BTT.6 The Novacor device, developed
by Peer Portner, was the first utilization of an elec-
trically powered implantable LVAD. Victor Porier and
colleagues at Thermo Cardiosystems, Inc. developed
the HeartMate IP1000, an implantable pneumatic, pul-
satile device that utilized a textured-blood contacting
surface that promoted cellular in-growth on the surface
and eliminated the need for anticoagulation therapy.2,5
O.H. Frazier of the Texas Heart Institute implanted this
device successfully as a BTT in 1988.5 The advantages
of an implantable VAD versus medical therapy as a BTT
were initially demonstrated in a multicenter clinical trial
of the HeartMate IP 1000 in 1992.2 In 1994, the Food
and Drug Administration (FDA) approved the use of the
pneumatically driven HeartMate IP 1000 implantable
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VAD as a BTT. Further clinical evaluation of the Novacor
LVAD and HeartMate VE (electrical-powered version of
the HeartMate IP 1000) LVAD led to approval of these
systems for BTT therapy by the FDA in 1998. These
systems represented the first wearable left ventricular
assist systems for BTT therapy that permitted hospital
discharge and outpatient management.
Direct randomized comparisons of VAD therapy to
medical therapy for BTT have never been performed
because of the ethical concerns for withholding po-
tentially life-saving therapy. However, VAD therapy
provides significant survival benefit and functional im-
provement compared to historical experiences or to
concurrent nonrandomized control patients treated
with medical therapy.2,3 Frazier et al. reported on 280
patients implanted with the HeartMate VE LVAD for
BTT therapy.3 Of the 280 patients, 71% survived long
term with 67% surviving to heart transplantation and
4% surviving to device explantation for myocardial
recovery. However, adverse events associated with
LVAD therapy utilizing the first generation of large pul-
satile devices were significant, and included bleeding
(31% of patients), infection (40% of patients), neu-
rologic dysfunction (5% of patients), thromboembolic
events (6% of patients), and major failure of the de-
vice (1% of patients). Survival on device support was
approximately 50% at one year, and posttransplant sur-
vival was 84% at one year. Similar results were also
reported for the Novacor LVAD by Dagenais et al.7
and Deng et al.8 although this device demonstrated
significantly enhanced long-term durability and relia-
bility over the HeartMate VE LVAD. In an analysis of
outcomes from patients implanted with the Novacor
LVAD in the Novacor European Registry, survival was
approximately 60% at one year for a cohort of 276
patients with lower-risk characteristics at implant, and
approximately 20% at one year for 90 patients with
high-risk characteristics at implant that included respi-
ratory failure with septicemia, preexisting right heart
failure, older age (>65 years), acute postcardiotomy
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etiology, and presentation with acute myocardial infarc-
tion.8 Major adverse events included bleeding, right
heart failure, respiratory infection, renal failure, stroke,
device pocket infection, and bacteremia. Sepsis was
the leading cause of death followed by organ failure,
bleeding, stroke, and other causes.
In addition to survival benefit, early studies of VAD
therapy have demonstrated improved recovery of or-
gan dysfunction, reversal of neurohormonal activation,
and improved exercise performance and rehabilitation
as compared to medical therapy.3,9–12 Improvements
in the cellular biology of the myocardium and overall im-
provement in left ventricular function also have been
reported following VAD therapy leading to the poten-
tial use of VAD therapy as a bridge to recovery and ob-
viating the need for heart transplantation.13,14 These
combined experiences and observations have led to a
significant increase in the number of patients BTT over
the past decade.
CURRENT OUTCOMES WITH VAD THERAPY FOR
BTT INDICATION
First-generation pulsatile, volume displacement de-
vices, until recently, were the mainstay of VAD
therapy for BTT with over 4000 devices implanted
worldwide. However, these devices have manifest
significant limitations in their design that preclude their
practical use for extended periods of MCS as a BTT
or as a permanent replacement for destination therapy
(DT). As waiting times for heart transplantation have
increased, extended periods of MCS highlighted limi-
tations in the design reliability and durability of pulsatile
pumps.15 These limitations included a large pump size
restricting mobility, requirement for extensive surgical
dissection for implant leading to bleeding and infec-
tion complications, a large body habitus of the recipi-
ent limiting options for device therapy for women, the
presence of a large-diameter percutaneous lead for
venting air, and audible pump operation.3,7 A critical
limitation of the these devices, particularly the Heart-
Mate VE device and the subsequent later model, the
HeartMate XVE, was the high incidence of reopera-
tion for device exchange for device malfunction.15,16
Reports on the HeartMate VE and XVE have demon-
strated a greater than 50% rate of device failure at
two years.15,16 The development of continuous-flow
(CF) rotary pump technology represents an innovative
design for VAD therapy and has now largely replaced
the use of large pulsatile volume replacement pumps
such as the HeartMate XVE and Novacor devices.17,18
The CF rotary devices have the advantage of a smaller
pump size and potential for greater mechanical relia-
bility by simplification of the pumping mechanism. Re-
ports from clinical trials of these newer pump designs
with axial blood flow have demonstrated efficacy in
providing hemodynamic support and improvements in
functional capacity and quality of life.17,18
The HeartMate II LVAD is a CF rotary pump with
axial design that is representative of the second gen-
eration of LVAD technology in clinical use in the
United States.17,18 Other second generation rotary
Figure 1. Survival analysis for patients receiving mechani-
cal circulatory support with a continuous-flow left ventric-
ular assist device (axial flow design) censored at the time
of heart transplantation and device explantation for cardiac
recovery.18
pump technology with axial blood flow design include
the DeBakey LVAD19 and Jarvik LVAD.20,21 The Heart-
Mate II LVAD recently completed an FDA evaluation
for BTT therapy in the United States in a cohort of
133 patients.17 Since this report, 336 additional pa-
tients have undergone implantation of the HeartMate II
LVAD as of April 2008 through a continued-access pro-
tocol approved by the FDA. To date, over 400 patients
have been evaluated with the HeartMate II LVAD for
BTT therapy and the device has received approval by
the FDA for BTT indication in May of 2008. In an ex-
tended follow-up report of 281 patients evaluated for
BTT therapy with the HeartMate II device, 222 (79%)
either received a transplant, recovered cardiac function
and underwent device explantation, or remained alive
with ongoing LVAD support at 18-month follow-up.18
At 18 months, 157 (55.8%) patients had received a
heart transplant, 58 (20.6%) remained alive with on-
going LVAD support, 56 (19.9%) patients died, seven
(2.5%) patients recovered cardiac function and under-
went device explantation, and three (1%) patients were
withdrawn from the study after device explantation and
exchange for another type of LVAD. Overall survival
for the patients who continued on LVAD support was
82% (95% confidence interval [CI]: 77% to 87%) at six
months, 73% (95% CI: 66% to 80%) at one year, and
72% (95% CI: 65% to 79%) at 18 months (Fig. 1). Of
the 157 patients that received a transplant, posttrans-
plant survival was 96% at 30 days and 86% at one
year. The primary causes of death were sepsis in 11
patients (4%), stroke in 10 (4%; ischemic: n = 5, 2%;
hemorrhagic: n = 5, 2%), and right heart failure in seven
(3%). Other causes included device-related deaths in
seven patients (3%), multiorgan failure in five (2%),
anoxic brain injury in three (1%), bleeding in three (1%),
and other causes in ten (4%; cancer, respiratory fail-
ure, hyperthermia, air embolism, and unknown). There
were a total of seven device-related deaths, four that
were attributed to malfunction of implanted compo-
nents (pump thrombosis in two, inflow graft that was
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disconnect in one), and three that were attributed to ex-
ternal components (severed percutaneous lead in one,
power loss in two). Only 13 of the deaths in the 281
(4.6%) patients (or 23% of the 56 deaths) occurred
after six months of device. Bleeding requiring trans-
fusion and surgery were the most common adverse
events in the study and were primarily observed within
the first 30 days of device implantation. Stroke was
observed in 25 (8.9%) patients, with the event rate
greatest in the first 30 days. Ischemic strokes were
more common than hemorrhagic strokes. After the
first 30 days, the event rates for ischemic and hem-
orrhagic stroke were 0.05 and 0.03 events per patient-
year, respectively. Six (2%) additional patients had
transient ischemic attacks that completely reversed.
Localized infection not related to the device occurred
in 84 (30%) patients. Infection associated with the per-
cutaneous lead was observed in 41 (14%) patients,
and there were five (2%) preperitoneal pump pocket
infections. Respiratory and renal failure occurred in 72
(26%) and 30 (11%) patients, respectively. Thirty-six
(13%) patients had right heart failure requiring inotrope
support for more than 14 days. Of the 53 (19%) pa-
tients that developed postoperative right heart failure,
survival with continued LVAD support at 18 months
was 62 ± 8%. Twenty-six of these 53 (49%) patients
with right heart failure received a transplant. Seven-
teen (6%) patients received temporary support with
right VADs (median time of support 11.5 days; range
0 to 148 days). The median duration of postoperative
inotrope support was nine days. A total of 11 (4%)
patients underwent 12 HeartMate II LVAD replace-
ments for either device thrombosis (n = 4; 1.4%; two
of whom subsequently died), surgical complications at
the time of LVAD implantation (n = 3; 1.1%), percuta-
neous lead wire damage (n = 4; 1.4%), or for develop-
ment of device infection (n = 1; 0.3%). One patient had
two of the pump replacements (thrombosis and infec-
tion). Of the 12 pump replacements, nine (75%) were
replaced with another HeartMate II LVAD, and the pa-
tients continued in the study, and three (25%) were
replaced with another type of LVAD device, and the
patients were withdrawn from the study. There were
no failures of the mechanical pumping mechanism.
The median time to pump replacement was 106 days
(range 0 to 672 days). The freedom from major device
malfunction resulting in death (n = 4) or device replace-
ment for all causes (malfunction, thrombosis, or infec-
tion; n = 9 without deaths) was 96% (95% CI: 95% to
99%) at six months, 93% (95% CI: 90% to 98%) at one
year, and 92% (95% CI: 88% to 97%) at 18 months
(Fig. 2). Functional assessment with six-minute walk
and NYHA functional classification were performed for
patients remaining on device support up to six months.
Of 109 patients with paired values at baseline and at
six months, only 14 of 109 (13%) were able to perform
a six-minute walk test at baseline, compared with 97
(89%) patients after six months of support, and there
was a significant improvement in distance walked be-
tween baseline and six months. Additionally, NYHA
functional classification improved from 3.9 ± 0.3 at
baseline (with 0% of patients in NYHA functional class
Figure 2. Analysis of freedom from major device malfunc-
tion as defined as the freedom from death as the result of
major device malfunction or need for device replacement
for all causes including device malfunction, thrombosis, or
infection.18
I or II) to 1.8 ± 0.7 at six months (with 83% in func-
tional class I or II). Quality of life assessed by both the
Minnesota Living With Heart Failure and the Kansas
City Cardiomyopathy Questionnaires was significantly
improved at six months compared with baseline, with
mean scores improving over 25 U, or 41% and 75%,
respectively. Hepatic (total bilirubin, serum aspartate
aminotransaminase, and serum alanine aminotransam-
inase) and renal (blood urea nitrogen) function sig-
nificantly improved from baseline to six months, but
changes in serum creatinine were not statistically
significant.
INFLUENCE OF VAD THERAPY ON
POSTTRANSPLANT OUTCOMES
Although VAD therapy significantly improves survival
to transplant for patients with advanced decompen-
sated heart failure, it has not been clear whether pa-
tients undergoing transplant with prior VAD support
have improved or decreased survival compared to pa-
tients undergoing transplant without prior VAD sup-
port. Studies to date have described an adverse, neu-
tral, or beneficial effect of implantable VAD therapy
on posttransplant survival.22–26 The differences in find-
ings of these studies are influenced by inclusion of
patients supported by short-term extracorporeal MCS
devices not intended for BTT indication, single cen-
ter versus multicenter reports, and whether posttrans-
plant survival following support VAD support was com-
pared to all transplant patients (UNOS status 1 and 2) or
UNOS status 1A or 1B patients with inotrope therapy
alone. The use of short-term extracorporeal VADs for
MCS as a BTT adversely influences early posttransplant
survival compared to patients supported with im-
plantable VADs at the time of transplantation.24,26 This
observation is likely attributed to the improved func-
tional status and improved status of organ function for
patients on implantable VAD support at the time of
transplant compared to patients supported with short-
term extracorporeal VADs. In a recent analysis of the
United Network for Organ Sharing Thoracic Registry,
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Patlolla et al.26 reported that the use of intracorporeal
VADs was associated with a small increase in mor-
tality in the first six months and a clinically significant
but small (2%) increase in mortality beyond five years.
However, the reasoning for a late adverse effect on
posttransplant survival from the pretransplant use of
VAD therapy is not well understood nor validated from
other studies of long-term transplant outcomes.
INTERAGENCY REGISTRY FOR MECHANICALLY
ASSISTED CIRCULATORY SUPPORT
The Interagency Registry for Mechanically Assisted
Circulatory Support (INTERMACS) database, funded by
the United States National Heart, Lung and Blood In-
stitute (NHLBI), is a registry for patients who receive
implantable and durable VAD devices that are approved
by the FDA.27,28 The INTERMACS registry represents
one of the largest available data repositories for the
study of VAD outcomes intended for BTT or DT. The
most recent published data analysis of MCS outcomes
for VAD therapy reviews the first 18 months of data
entry into the registry and almost exclusively repre-
sent outcomes from patients undergoing implantation
with the first generation of pulsatile, volume displace-
ment technology such as the HeartMate XVE, Thor-
atec post-VAD (pVAD), Thoratec IVAD, and Novacor
LVAD.28 Survival with VAD support at one year was
approximately 60% for all patients and significantly
worse for those patients requiring biventricular assist
device (BiVAD) support or support with a total artifi-
cial heart compared to patients requiring LVAD support
alone.27,28 (Figs. 3 and 4) Patients undergoing implan-
tation of a device in the presence of critical cardiogenic
shock (i.e., INTERMACS level 1) had worse outcomes
compared to device implantation in patients with more
stable forms of advanced heart failure (INTERMACS
levels 2 through 7)28 (Fig. 5). These observations high-
light the importance of proper patient selection and
Figure 3. Survival analysis for patients on mechanical cir-
culatory support and entered into the INTERMACS Reg-
istry from June 2006 through December 2007. (Figure ob-
tained from the INTERMACS Registry website: http://www.
uab.edu/ctsresearch/intermacs/presentations.htm and previ-
ously presented at the International Society of Heart and Lung
Transplantation, 28th Meeting and Scientific Sessions, April
2008.)28
Figure 4. Survival analysis of patients on mechanical circu-
latory support and entered into the INTERMACS Registry
from June 2006 through December of 2007 and stratified
by device location. (LVAD = left ventricular assist device;
RVAD = right ventricular assist device; BiVAD = biventric-
ular assist device; TAH = total artificial heart). (Figure ob-
tained from the INTERMACS Registry website: http://www.
uab.edu/ctsresearch/intermacs/presentations.htm and previ-
ously presented at the International Society of Heart and Lung
Transplantation, 28th Meeting and Scientific Sessions, April
2008.)28
timing of initiation of VAD therapy on pVAD outcomes.
Patients with significant organ dysfunction at the time
of LVAD implant, accompanied by a greater degree of
hemodynamic compromise, have a significantly higher
risk of requiring BiVAD support, higher risk of major
adverse events, and significantly higher risk of death
during VAD support.2–4 Thus, hemodynamic stability
provided with inotrope support, INTERMACS level 3,
appears to be a reasonable threshold and indication
for LVAD therapy. This clinical threshold appears to
maximize post-LVAD survival. Implantation of a device
for less advanced stages of heart failure, INTERMACS
Figure 5. Survival analysis of patients on mechanical circula-
tory support and entered into the INTERMACS registry from
June 2006 through December 2007 stratified by acuity of ill-
ness assessed by the INTERMACS patient profile. (Figure ob-
tained from the INTERMACS Registry website: http://www.
uab.edu/ctsresearch/intermacs/presentations.htm and previ-
ously presented at the International Society of Heart and Lung
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levels 4 through 7, does not appear to offer survival ad-
vantage over implantation of a device at INTERMACS
level 3. Prospective, randomized studies will likely be
required to determine the benefit of LVAD therapy at
less advanced stages of heart failure.
Since May of 2008, following FDA approval of Heart-
Mate II LVAD, an increasing number of patients en-
tered into the INTERMACS registry have received VAD
support with the new generation of CF rotary technol-
ogy. Subsequent reports from the INTERMACS reg-
istry will highlight outcomes from new CF rotary pump
technology and offer unique insight with comparison
to older technology for BTT indication.
NEWER DEVICE DESIGNS FOR BTT THERAPY
Although significant improvements in pump design
have occurred with the second generation of CF ro-
tary pumps (axial design), there remain a number of
potential concerns with this technology. The presence
of contact bearings to suspend the rotor represents
a potential point of frictional wear resulting in de-
vice failure and subsequent need for device exchange.
The second-generation pump technology still demon-
strates the potential for thrombus formation on the
device rotor and bearing interface due to the presence
of stasis and incomplete bearing wash.17,29 However,
the concern for development of thrombus on the ro-
tor and bearing contact points has varied significantly
with different second-generation rotary pumps.29 The
presence of stators to suspend and redirect blood flow
also represents an obstruction within the blood flow
path. Thrombosis from blood stasis can be caused by
blood flow disturbances and recirculating zones asso-
ciated with the supports required by contact bearing
design. Clinical studies have documented the prob-
lem with device thrombus requiring device exchange
or treatment with thrombolytic therapy, and have also
shown a reduced but persistent risk of stroke.17,29 A
significant proportion of strokes reported during clini-
cal trials with second-generation devices have occurred
early following surgery and were associated with the
implant procedure, likely representing air or particulate
emboli possibly from sources other than the device.
The proportion of strokes that are attributable to tran-
sient thrombus formation within the pump or throm-
bus formation within the heart is unknown. In addition,
this technology still requires long-term antithrombotic
therapy and subsequently, hemorrhagic complications
are observed with this therapy. The designation of the
new third generation of rotary pumps has generally
been used to categorize CF rotary devices with an im-
peller or rotor suspended in the blood flow path using a
noncontact-bearing design.30 In the majority of circum-
stances this design utilizes a “centrifugal” blood flow
path and incorporates either magnetic and/ or hydrody-
namic levitation of the internal impeller. Currently, CF
pumps with centrifugal and noncontact-bearing design
in clinical trial evaluation in the United States include
the DuraHeart LVAD (Terumo Heart Corporation, Ann
Arbor, MI, USA) and HVAD (HeartWare Corporation,
Miami, FL, USA).31–33
The DuraHeart LVAD is a CF rotary pump with cen-
trifugal and noncontact-bearing design.32 The device
has a displacement volume of 180 cm3 and a weight
of 540 g. Its external dimensions are 72 mm in width
and 45 mm in height. The pumping unit consists of
an upper housing with the levitation system, impeller,
and bottom housing containing the external-drive mo-
tor. The device is designed with active magnetic lev-
itation of the impeller along with hydrodynamic bear-
ings to support impeller levitation in case of failure of
the magnetic levitation system. The impeller is rotated
through magnetic coupling between permanent mag-
nets embedded on the motor side of the impeller and
an external-drive motor that utilizes a bearing design.
Three electromagnets and three position sensors are
mounted in the upper housing. Tilting and axial dis-
placements of the impeller are monitored and con-
trolled using a three-degrees-of-freedom control. The
ferromagnetic ring on the opposite side of the impeller
is levitated by the electromagnet, and position sensors
control the impeller so that it is always positioned at
the center of the blood chamber. Radial impeller move-
ment is passively suspended with a bias flux through
electromagnetic rotor and drive magnet rotor.
Clinical evaluation of the DuraHeart device has re-
cently concluded in Europe, and clinical evaluation of
the device in the United States began in July of 2008.
A preliminary report of the European experience was
recently presented at the International Society of Heart
and Lung Transplantation in April of 2008.32 Thirty-five
patients with advanced heart failure (NYHA class IV,
14 ischemic, five females) who were eligible for heart
transplantation underwent implantation of the Dura-
Heart device from January of 2004 through September
of 2007. Median age of the patients was 56 (range 29
to 73) years with a median body surface area of 1.9
(1.4 to 2.4) m2. The average duration of device sup-
port was 330 ± 220 (17 to 808) days with a cumulative
duration of 21 years. Fourteen patients (40%) under-
went heart transplantation at 194 ± 146 days. Nine-
teen patients (54%) were supported for at least six
months and seven (20%) patients were supported for
greater than one year. Fourteen patients (40%) remain
alive with ongoing device support (330 ± 292 days).
Kaplan–Meier survival at two years was 78%. There
were seven deaths (median time to deaths: 29 days).
Six early deaths occurred for the initial 11 patients
and four were associated with excessive anticoagula-
tion/antiplatelet therapy that resulted in fatal intracere-
bral hemorrhage or subdural hematoma. After imple-
menting less intensive anticoagulation and antiplatelet
therapy comparable to mechanical heart valves, there
was no ischemic or hemorrhagic stroke for the last 24
patients. Stroke-free survival for the last 24 patients
was 94% at two years. Twenty-six patients (86% of
one-month survivors) were discharged home, and the
readmission rate was 1.5/pt-year. There was no pump
mechanical failures, pump thrombosis, or hemolysis
throughout the support duration.
The HVAD is a small CF rotary pump with centrifu-
gal and noncontact-bearing design.33 The unique fea-
ture of the HVAD is its small design size. It has a
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displacement volume of 45 cc, and weighs 145 g with
a flow capacity of up to 10 L/min. The HVAD impeller
is suspended in place by combination of passive mag-
netic and hydrodynamic bearing systems to avoid me-
chanical contact and wear. The design integrates two
motor stators for single-motor fault protection to in-
crease reliability. The impeller suspension system uses
a passive magnetic bearing for radial stiffness. Axial
magnetic preload and hydrodynamic bearings on top
of each impeller blade provide axial constraint.
The HVAD has undergone clinical evaluation in
Europe and Australia and clinical evaluation in the
United States began in May of 2008. In a multi-
institutional trial in Europe and Australia, 20 patients
underwent implantation of the HVAD from March of
2006 through September of 2007.34 Mean age of the
patients was 46 ± 12 (range 28 to 68 years) years.
Median cardiopulmonary bypass time to implant the
device was 67 min (range 21 to 140 min). Mean du-
ration of HVAD device support was 167 ± 143 days
(range 13 to 425 days). Range of blood flow provided
by the pump was 4.0 to 6.5 L/min. Three patients were
successfully transplanted after 426, 349, and 157 days,
respectively. One patient was weaned from pump sup-
port on postoperative day 266, two patients died on de-
vice (postoperative days 13 and 203), and 14 patients
remain alive with ongoing device support. Actuarial sur-
vival at one year was 80%.
CONCLUSIONS
Implantable VAD therapy is an established and vi-
able treatment option for patients with advanced heart
failure awaiting heart transplantation. Over the past
decade, there has been a transition from pulsatile
pumps to CF rotary pumps with axial and, more re-
cently, centrifugal blood flow design. This transition
to new technology has been associated with im-
provements in pump design contributing to a signif-
icant reduction in the occurrence of serious adverse
events, particularly pump malfunction, device-related
infection, and right heart failure. Bleeding, stroke,
and thromboembolic events remain an important con-
cern with VAD therapy. An improved understanding
of the biology of the blood-device interface is neces-
sary to understand optimal management of anticoag-
ulation and device design to prevent these adverse
events.
The majority of patients undergoing LVAD therapy
as a BTT currently receive device intervention at signif-
icant stages of advanced, progressing or decompen-
sated heart failure or cardiogenic shock (INTERMACS
levels 1 and 2). This is obviously unavoidable for those
patients presenting with acute hemodynamic change.
However, current data suggest that intervention at less
advanced stages, INTERMACS level 3 (stable on in-
otrope therapy), maximizes postimplant survival. Appli-
cation of new device technology along with improved
timing of intervention for those patients experiencing
progressive decline will likely increase the overall ef-
fectiveness of LVAD therapy as a BTT.
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